| (Values in U.S. Thousands) | Mar, 2023 | Jun, 2022 | Mar, 2022 | Mar, 2023 | Jun, 2022 |
| Sales | 5,078 | 6,461 | 5,844 | 0 | 0 |
| Sales Growth | -21.41% | +10.56% | unch | unch | unch |
| Net Income | -3,609 | -98 | -528 | 0 | 0 |
| Net Income Growth | -3,582.65% | +81.44% | unch | unch | unch |
Spectral MD Holdings Ltd (SMD.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Spectral MD Holdings Ltd is a predictive analytics company that develops proprietary optical technology and AI algorithms to help clinicians make more accurate and faster treatment decisions in the wound care sector. Using its DeepView Wound Imaging Device, an internally developed multispectral imaging device which has designated FDA Breakthrough status, the Company is able to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments for burn wounds and diabetic foot ulcers (DFU).
Fiscal Year End Date: 12/31